Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease.
Wang Y, Rollins S, Madri J, Matis L. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proceedings Of The National Academy Of Sciences Of The United States Of America 1995, 92: 8955-8959. PMID: 7568051, PMCID: PMC41086, DOI: 10.1073/pnas.92.19.8955.Peer-Reviewed Original ResearchConceptsCollagen-induced arthritisRheumatoid arthritisComplement activationAnti-C5 mAbInflammatory joint diseaseOnset of arthritisMonoclonal antibody therapyTerminal complement activationAttractive therapeutic targetJoint inflammationAntibody therapySystemic administrationJoint diseaseNumerous disease statesImmunized animalsArthritisAnimal modelsTherapeutic targetPotent mediatorTerminal complement componentsActivated componentsComplement cascadeComplement componentsComplement systemMonoclonal antibodies